

Figure S1. Immunohistochemistry for the specificity of anti-PALB2 antibodies. Surgical samples from stomach (upper panels) and breast cancer (lower panels) were analyzed by immunohistochemistry (magnification, x400; n=3 patients per group).




Figure S2. Inhibition of PALB2 expression in pancreatic ductal adenocarcinoma cells. (A) Reverse transcription-quantitative PCR indicated successful PALB2-knockdown by siRNA in PANC1 and CFPAC1 cell lines. (B) Migration analysis of cells following PALB2-knockdown as determined by a wound healing assay (magnification, x100). (C) Cell proliferation rates were not affected by PALB2-knockdown in PANC1 cells. (D) PALB2-knockdown suppressed cell proliferation in CFPAC1 cells. Biological triplicates were analyzed using an unpaired Student's t-test. * $P < 0.05$; *** $P < 0.001$. OD, optical density; NC, negative control; siRNA, small interfering RNA; PALB2, partner and localizer of BRCA2.




Table SI. Distribution of the IHC scores among PDAC (n=157) and peritumoral tissues (n=121).

IHC score	PDAC tissues, n (%)	Peritumor tissues, n (%)
0	93 (59.2)	91 (75.2)
1	26 (16.6)	27 (22.3)
2	22 (14.0)	2 (1.7)
3	7 (4.5)	0 (0.0)
4	9 (5.7)	1 (0.8)

IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma.

Table SII. Clinicopathological characteristics of 178 patients with PDAC and PALB2 expression in PDAC samples represented in The Cancer Genome Atlas database (May 2019).

Features	High PALB2 expression, n=89	Low PALB2 expression, n=89	P-value
Mean age \pm SD, years	65.8 \pm 11.0	63.4 \pm 10.8	0.1393
Sex, n (%)			0.4513
Male	46 (51.7)	52 (58.4)	
Female	43 (48.3)	37 (41.6)	
TNM staging, n ^a (%)			0.0099 ^b
T1-2	9 (10.0)	22 (25.0)	
T3-4	79 (90.0)	66 (75.0)	
N stage, n ^a (%)			0.8661
N0	24 (27.2)	27 (39.7)	
N1	64 (63.8)	61 (60.3)	
AJCC staging, n ^a (%)			0.6151
I-IIA	23 (26.1)	26 (29.5)	
IIB-IV	65 (73.9)	62 (70.5)	
Tumor location, n (%)			>0.9999
Head	69 (77.5)	70 (78.6)	
Body/Tail	20 (22.5)	19 (21.4)	

^an=176. ^bP<0.05. PDAC, pancreatic ductal adenocarcinoma; PALB2, partner and localizer of BRCA2.